RXi Pharmaceuticals Corp. (RXII) announced today that The U.S. Food and Drug administration has cleared the CMC partial clinical hold, allowing the pivotal Phase 3 trial of NeuVax to commence. NeuVax is expected to initiate its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax(TM) […]